Published January 30, 2025
| Version v1
Publication
Open
A Comprehensive Diagnostic and Treatment Framework for Pancreatic Cancer Patients with Comorbidities
Creators
- 1. MD, PhD, Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- 2. MD, MS, Weill Cornell Medical College of Cornell University
- 3. MD, MS, Nexus Alliance Biopharma
- 4. Ms, Islamic Azad University
- 5. PharmD, Nexus Alliance Biopharma
- 6. Student at the University of Florida
- 7. Student at York University, Toronto, ON
- 8. Student at Valencia College
Description
Abstract
Pancreatic cancer remains a challenging malignancy with a high mortality rate. Comorbidities such as chronic pancreatitis, diabetes mellitus, obesity, and metabolic syndrome exacerbate diagnostic and treatment challenges, significantly influencing outcomes. [1] This study evaluates the impact of comprehensive comorbidity management including glycemic control, weight management, and anti-inflammatory therapies, on overall survival (OS) and overall response rate (ORR). [2] Analysis of 2,600 biomarker datasets and 124 patient records from a retrospective cohort revealed that effective comorbidity management was associated with improved OS (hazard ratio: 0.75 [95% CI, 0.65–0.85]; p < 0.01) and ORR (response rate: 45% vs. 30%, p = 0.02) compared to patients with unmanaged conditions. A comparative analysis with population-based registry data further highlights the need to tailor diagnostic and therapeutic strategies for high-risk cohorts, emphasizing the importance of addressing comorbidities in pancreatic cancer management. [3].
Files
JMRCR-07-0064.pdf
Files
(485.2 kB)
Name | Size | Download all |
---|---|---|
md5:e8df695a56415da86eb603d47f06ae22
|
485.2 kB | Preview Download |